- Accesswire•3 days ago
LOS ANGELES, CA / ACCESSWIRE / December 1, 2016 / Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that Company management ...
- Business Wire•11 days agoRosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement Offering
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostic testing services, today announced it has entered into definitive agreements with one prominent institutional healthcare investor to purchase an aggregate of 1,095,000 ordinary shares at a purchase price per share of $0.50 and registered convertible debentures in a registered direct offering, as ...
- Business Wire•13 days agoRosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab, an immunotherapy drug marketed as Opdivo®, which is approved for the treatment of lung cancer patients.
ROSG : Summary for Rosetta Genomics Ltd. - ordinar - Yahoo Finance
Rosetta Genomics, Ltd. (ROSG)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.59 x 6100|
|Ask||0.64 x 500|
|Day's Range||0.58 - 0.62|
|52 Week Range||0.55 - 1.60|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.61|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|